PF-5006739

• UNSPSC Description:

  PF-5006739 is a potent and selective inhibitor of CK1δ/ε with IC50s of 3.9 nM and 17.0 nM, respectively. PF-5006739 is a potential therapeutic agent for a range of psychiatric disorders with low nanomolar in vitro potency for CK1δ/ε and high kinome selectivity. PF-5006739 attenuats opioid agent-seeking behavior in a rodent operant reinstatement model in animals in a dose-dependent manner[1]. PF-5006739 improves glucose tolerance in both diet-induced obesity (DIO) and genetic (ob/ob) mice models of obesity[2].

• Target Antigen:

  Casein Kinase

• Type:

  Reference compound

• Related Pathways:

  Cell Cycle/DNA Damage;Stem Cell/Wnt

• Field of Research:

  Neurological Disease

• Assay Protocol:

  https://www.medchemexpress.com/pf-5006739.html

• Purity:

  99.56

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  NC1=NC=CC(C2=C(C3=CC=C(F)C=C3)N=CN2C4CCN(CC5=NOC=C5)CC4)=N1

• Molecular Weight:

  419.45

• References & Citations:

  [1]Wager TT, et al. Casein kinase 1δ/ε inhibitor PF-5006739 attenuates opioid drug-seeking behavior. ACS Chem Neurosci. 2014 Dec 17;5(12):1253-65.|[2]Cunningham PS, et al. Targeting of the circadian clock via CK1δ/ε to improve glucose homeostasis in obesity.Sci Rep. 2016 Jul 21;6:29983.

• Shipping Conditions:

  Room Temperature

• Storage Conditions:

  4°C (Powder, protect from light)

• Clinical Information:

  No Development Reported

• CAS Number:

  1293395-67-1